.Charles Baum, M.D., Ph.D., who oversaw Mirati Therapies' $ 5.8 billion sale to Bristol Myers Squibb in 2014, is taking the command of younger biotech Terremoto Biosciences.Baum's "extensive experience in medication development, as well as tried and tested track record beforehand high-impact medications, will definitely contribute," outward bound CEO Peter Thompson, M.D., claimed in a July 25 release. Thompson is going to keep his chair as board chairperson..Baum, an experienced physician-scientist, was actually the creator, head of state and CEO of oncology-focused Mirati. Just before that, he assisted build cancer medications at Pfizer as well as Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will definitely act as CEO at Terremoto, a provider creating little molecules to target disease-causing proteins-- like those located in malignant growth tissues-- making use of covalent bonds. Existing treatments that use covalent connects largely target the amino acid cysteine. Nonetheless, of the 20 amino acids that comprise healthy proteins, cysteine is actually the least common. Terremoto is rather targeting among the necessary amino acids, lysine, which is found in mostly all proteins.Through targeting lysine and also various other amino acids, Terremoto hopes to address previously undruggable ailments as well as make first-in-class medications..The biotech, located in South San Francisco, reared $75 thousand in series A backing in 2022. A little bit of more than a year eventually, the biotech much more than doubled that amount in a $175 thousand set B.